The government of India introduced the injectable contraceptive Medroxyprogesterone Acetate (MPA-Antara) in the national family planning programme. What is the dosing schedule for this injectable?
- A 1 mg subcutaneously weekly
- B 104 mg subcutaneously monthly
- C 150 mg intramuscularly every 3 months ✓
- D 200 mg intramuscularly every 6 months
Explanation
Medroxyprogesterone Acetate (DMPA) depot injection — marketed as Antara under India's national family planning programme — is given as 150 mg intramuscularly every 3 months (quarterly). It works by suppressing ovulation, thickening cervical mucus, and thinning endometrium. It is particularly suitable for breastfeeding women (progestogen-only), women who cannot use oestrogen-containing contraceptives, and those who desire spacing without requiring daily pill compliance. The 104 mg subcutaneous form (DMPA-SC) is available globally but not the primary Indian government formulation.
Reference: Park's Textbook of Preventive and Social Medicine, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.